Symptomatic treatment of Alzheimer's disease: identification of biomarkers to aid translation from bench to bedside.
In the absence of robust pharmacodynamic markers, the potential success of novel therapeutic agents for the symptomatic relief of Alzheimer's disease is largely unknown until the drugs enter relatively large studies, assessing clinical outcome over a 6-month period. In order to increase the efficiency of future clinical development there is, therefore, a need to identify pharmacodynamic markers of drug response, pharmacodynamic models that allow early prediction of efficacy and markers to aid the stratification of the patient population. Using literature available from cholinesterase inhibitors, memantine and Ginkgo biloba, this review focuses on the identification of potential pharmacodynamic markers/models and highlights the utility of these end points throughout the drug discovery process, from preclinical to clinical development.
Irving
Elaine A
EA
GlaxoSmithKline, Neurology and GI CEDD, New Frontiers Science Park North, Third Avenue, Harlow, Essex, CM19 5AW, UK. elaine.a.irving@gsk.com
Upton
Neil
N